Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ferguson, J.
Right arrow Articles by Willavize, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ferguson, J.
Right arrow Articles by Willavize, S. A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2000) 45, 503-509
© 2000 The British Society for Antimicrobial Chemotherapy

A comparison of the photosensitizing potential of trovafloxacin with that of other quinolones in healthy subjects

J. Fergusona,*, J. McEwenb, H. Al-Ajmia, L. Purkinsc, P. J. Colmanc and S. A. Willavized

a Photobiology Unit, University of Dundee and b Drug Development (Scotland) Ltd, Ninewells Hospital and Medical School, Dundee DD1 9SY; c Pfizer Central Research, Sandwich CT13 9NJ, UK; d Pfizer Central Research, Groton, CT, USA

Treatment with some quinolones is associated with an abnormal skin reaction following exposure to sunlight (photosensitivity). The objective of the current study was to compare the photosensitizing potential of a new quinolone, trovafloxacin, with that of ciprofloxacin, lomefloxacin and placebo. Forty-eight healthy males (age range 19–45 years) were randomized to receive a 7 day course of treatment with: (i) trovafloxacin 200 mg od; (ii) ciprofloxacin 500 mg bd; (iii) lomefloxacin 400 mg od; or (iv) placebo bd. Minimal erythema doses (MEDs) were assessed using a monochromator at baseline and on day 5 of treatment, for wavelengths of 305 ± 5, 335 ± 30, 365 ± 30, 400 ± 30 and 430 ± 30 nm; 335 ± 30 and 365 ± 30 nm are within the UVA range. Immediate reaction MEDs were similar in all treatment groups. However, between baseline and day 5, the mean decreases in delayed-reaction MED (24 h) at 335 ± 30 nm were only 18.99% for trovafloxacin versus placebo (P = 0.1267), compared with 53.77% (P 0.0001) and 64.13% (P 0.0001) for ciprofloxacin and lomefloxacin, respectively. Similarly, at 365 ± 30 nm, trovafloxacin produced the smallest reduction in delayed MED versus placebo (43.66%), compared with ciprofloxacin (61.53%) and lomefloxacin (75.81%). These differences between trovafloxacin and ciprofloxacin and lomefloxacin were significant at both 335 ± 30 and 365 ± 30 nm (P 0.029). All MED values returned to baseline levels within 2 days of drug cessation. These results show that trovafloxacin has significantly less photosensitizing potential than either ciprofloxacin or lomefloxacin. This photosensitivity appears to be induced only by wavelengths in the UVA region, is maximal at 24 h and is a short-term effect.

* Corresponding author. Tel: +44-1382-632240; Fax: +44-1382-646047.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Chronic Respiratory DiseaseHome page
T. Lee
Eradication of early Pseudomonas infection in cystic fibrosis
Chronic Respiratory Disease, May 1, 2009; 6(2): 99 - 107.
[Abstract] [PDF]


Home page
The OncologistHome page
G. A. Dawson, S. I. Brown, and L. Tellefsen
A Drug-Related Phototoxic Reaction and Its Possible Relationship to a Radiation-Induced Skin Reaction
Oncologist, March 1, 2009; 14(3): 303 - 306.
[Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
M. E. Falagas, D. K. Matthaiou, and K. Z. Vardakas
Fluoroquinolones vs {beta}-Lactams for Empirical Treatment of Immunocompetent Patients With Skin and Soft Tissue Infections: A Meta-analysis of Randomized Controlled Trials
Mayo Clin. Proc., December 1, 2006; 81(12): 1553 - 1566.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.